Brilinta, a new antiplatelet drug

You'll hear lots of buzz about Brilinta, a new antiplatelet drug.

Brilinta (ticagrelor) will compete with Plavix (clopidogrel) and Effient (prasugrel)...for acute coronary syndrome or after a stent.

Plavix will still lead the pack...for a while. It was the first one approved and is used the most. But it's not perfect.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote